Home LiteratureArticle Details
PMID: 440817 Published · ppublish English Journal Article

Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products.

Pediatrics ·Vol. 63 ·No. 2 ·1979-02-00 ·Pages 256-60

Barkin RM, Pichichero ME

Abstract

Parents from four practices were surveyed to ascertain reactions of children to diphtheria-pertussis-tetanus (DPT) vaccine in the 48 hours after immunization. Vaccines were administered according to current recommendations. Responses were scored in three categories: temperature, behavioral changes, and local reactions. Questionnaires were returned by 1,232 (84.9%) patients. Only 7.0% reported no reaction, while 336 (27.3%) reported mild, 722 (58.6%) moderate, and 88 (7.1%) severe reactions. Over 50% experienced temperatures of at least 100 F, and 80% noted behavioral changes; 72.2% had local reactions. No encephalitis, seizures, or hospitalizations were reported. Reactogenicity was similar for the five immunizations of the recommended series and the two manufacturers evaluated. Reported reactions in the control group were significantly lower than in the study group. These reaction rates underline the need to reevaluate present DPT vaccines.

MeSH Terms
Child Behavior/drug effects Child, Preschool Diphtheria/immunology Drug Hypersensitivity/etiology Fever/chemically induced Humans Immunization, Secondary Infant Pertussis Vaccine/adverse effects Tetanus/immunology Vaccination/adverse effects
Chemicals
Pertussis Vaccine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Barkin R M
Pichichero M E
Article Info
Journal
Pediatrics
Abbr.
Pediatrics
ISSN
0031-4005
Published
1979-02-00
Pages
256-60
Language
English
Region
United States
NLM ID
0376422
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]